Table 3 |
||||||
|
Immunohistochemical Results, Tumor Cell Expression |
||||||
|
Marker |
Thymoma Type |
|||||
|
|
||||||
|
A |
AB |
B1 |
B2 |
B3 |
MNT |
|
|
|
||||||
|
EMA |
+ |
+ |
Focal |
S |
+ |
+ |
|
CK7 |
+ |
+^ |
+ |
+ |
+ |
+ |
|
CK20 |
- |
- |
- |
- |
- |
- |
|
CD57 |
S |
S |
S |
+* |
+* |
+ |
|
CD5 |
- |
- |
- |
- |
-/+ |
- |
|
Bcl-2 |
- |
- |
- |
- |
-/+ |
- |
|
Calretinin |
S |
S |
S |
S |
S |
S |
|
Vimentin |
+ |
+ |
- |
- |
- |
- |
|
CD20 |
+ |
+ |
- |
- |
- |
- |
|
|
||||||
|
MNT= micronodular thymoma S = single cells +^ = neoplastic epithelial cells in type B component were CK7 negative -/+ = variably (2 sporadic type B3 thymomas stained strongly positive) +* = strong expression in type B2 (n = 1) and type B3 (n = 3) thymomas associated with autoimmune disorder; scattered positive neoplastic cells in sporadic thymomas |
||||||
|
Alexiev et al. Diagnostic Pathology 2007 2:13 doi:10.1186/1746-1596-2-13 |
||||||
